Nyheter/rapporter

Senaste pressmeddelanden och rapporter för bevakat bolag.

Datum Källa Rubrik Typ Alternativ
2022-08-11 Immunovia Immunovia AB: Immunovia, Inc. erhåller licencsrättigheter från hälsodepartementet i Kalifornien för IMMray® PanCan-d-test Pressreleaser Ladda ner | Visa Stäng
2022-08-11 Immunovia Immunovia AB: Immunovia, Inc. Issued Clinical and Public Health Laboratory License from California Dept of Public Health for IMMray™ PanCan-d test Pressreleaser Ladda ner | Visa Stäng
2022-07-05 Immunovia Immunovia AB: CPT PLA-kod för testet IMMray® PanCan-d godkänt Pressreleaser Ladda ner | Visa Stäng
2022-07-05 Immunovia Immunovia AB: CPT PLA Code for the IMMray™ PanCan-d test approved Pressreleaser Ladda ner | Visa Stäng
2022-06-30 Immunovia Immunovia AB: The PanDIA-1 study, for early detection of pancreatic cancer in newly onset type 2 diabetics, moves into next phase Pressreleaser Ladda ner | Visa Stäng
2022-06-30 Immunovia Immunovia AB: PanDIA-1-studien för tidig upptäckt av bukspottkörtelcancer vid typ 2-diabetes går vidare till nästa fas Pressreleaser Ladda ner | Visa Stäng
2022-06-27 Immunovia Immunovia AB: Inbjudan till Immunovias presentation av resultat för PanFAM-1 Pressreleaser Ladda ner | Visa Stäng
2022-06-27 Immunovia Immunovia AB: Invitation to Immunovia's Presentation of PanFAM-1 Results Pressreleaser Ladda ner | Visa Stäng
2022-06-27 Immunovia Immunovia AB: PanFAM-1 Results Partly Inconclusive Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 27 Jun 2022 | Immunovia

Immunovia AB: PanFAM-1 Results Partly Inconclusive

”We aimed for more tangible results of the PanFAM-1 study, which are partly inconclusive due to a variety of factors related to the execution of the clinical trial compared with original study design. The PanFAM-1 clinical study was also impacted by the COVID pandemic, when many hospitals were closed for the routine surveillance or screening of patients, as many others in the industry have experienced”, said Philipp Mathieu, CEO and President of Immunovia AB.

Analysis of the sensitivity of IMMray™ PanCan-d in the PanFAM-1 study was confounded by the unexpectedly low 0.2% prevalence of PDAC in the PanFAM-1 cohort, which was lower than the c.1% prevalence in this risk group observed in other studies1, 2 and was lower than the prevalence assumed in the study design. In addition, the execution of the study was compromised by the following factors:

  • The COVID pandemic significantly impacted the recruitment and monitoring of patients
  • Insufficient number of serial blood draws and/or imaging for each patient
  • Failure to provide a quality/accuracy assessment of imaging results

Philipp Mathieu, CEO and President of Immunovia AB, continues: ”We are very grateful to the patients, clinicians and hospitals who participated in this study. In close collaboration with key opinion leaders and participating study sites we are currently analyzing the important learnings from PanFAM-1 which together with our ongoing discussions with payers will inform the way forward in establishing further clinical validation in this risk group.”

Analysts, investors and media are invited to a webcast and teleconference, today Monday, June 27, at 13:00 pm CET for a presentation of the outcome and learnings from the PanFAM-1 study. For details, see the end of the press release.

PanFAM-1, background and details

PanFAM-1 was the first prospective, multi-center trial initiated by Immunovia in 2016, with the goal of evaluating the performance (sensitivity and specificity) of the IMMray™ PanCan-d test in individuals at high risk for developing familial or hereditary pancreatic ductal adenocarcinoma (PDAC) in comparison to conventional imaging.

Individuals enrolled in PDAC surveillance programs were planned to receive imaging and clinical evaluation at least once per year consistent with the study center’s protocol (MRI, EUS or CT) and had a blood draw every 6 months. As an observational study, blood samples were frozen and stored until the IMMray™ PanCan-d test was clinically validated.

Samples were collected at 23 sites in the US (14) and Europe (9), with 3,457 blood samples collected from 1,255 participants between January 2016 and November 2021. Sites in the U.S. contributed over 2,300 blood samples from two third of the study participants, with a median observation period of 1-2 years. The IMMray™ PanCan-d results for US participants were in line with those reported for the US PanFAM-1 subjects in the blind validation (88.8% negative, 9.5% borderline, and 1.7% positive) [Clinical and Translational Gastroenterology, 2022; doi.10.14309/ctg.0000000000000468]. 

Statistical comparison of specific imaging findings and IMMray™ PanCan-d results is ongoing to examine trends in IMMray™ PanCan-d results relative to specific germline mutations, family histories, and imaging findings at the direction of the Principal Investigators in this study. Independent analysis of the PanFAM-1 results was conducted by Biostatisticians at the Biostatistical and Epidemiological Data Analysis Center (BEDAC) at Boston University School of Public Health.

[1] Overbeek KA, Levink IJ, Koopmann BDM et al. Long-term yield of pancreatic cancer surveillance in high-risk individuals. Gut. 2022;71:1152-1160.
[2]Overbeek KA, Goggins MG, Dbouk M et al. Timeline of development of pancreatic cancer and implications for successful early detection in high-risk individuals. Gastroenterol. 2022;162:772-785.

Details for webcast and teleconference

Analysts, investors and media are invited to a webcast and teleconference today, Monday June 27 at 13:00 pm CET. The presentation slides will be available at www.immunovia.com.

The presentation will be held in English and be followed by a Q&A session. You are welcome to join via webcast or phone, see details below.

Telephone numbers and webcast

Ring any of the numbers below to participate via telephone. Please dial in a few minutes before the presentation starts.

Sweden: +46 8 50 51 00 31

United Kingdom: +44 207 107 06 13

United States: +1 631 570 56 13

Link to the webcast: https://creo-live.creomediamanager.com/806a27cb-a49a-4fa9-b7e7-3ac9fd7a4795

To ask questions, it is necessary to dial in. A recording of the presentation will be available on Immunovia’s website.

For more information, please contact:

Philipp Mathieu

CEO and President

philipp.mathieu@immunovia.com

Tobias Bülow

Senior Director Investor Relations and Corporate Communications
tobias.bulow@immunovia.com
+46736 36 35 74

This is information that Immunovia is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CET June 27, 2022.

About Immunovia
Immunovia AB is a diagnostic company with the vision to revolutionize blood-based diagnos­tics and increase survival rates for patients with cancer.

Our first product, IMMray™ PanCan-d is the only blood test currently available specifically for the early detection of pancreatic cancer. The test has unmatched clinical performance. Commercializa­tion of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com

Immunovia collaborates and engages with healthcare providers, leading experts and patient ad­vocacy groups globally to make this test available to all high-risk pancreatic cancer groups.

The USA, the first market in which IMMray™ PanCan-d is commercially available, is the world’s largest market for the detection of pancreatic cancer with an estimated value of more than USD 4 billion annually.

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit: www.immunovia.com.

                                                                             ###

2022-06-27 Immunovia Immunovia AB: Resultat för PanFAM-1 delvis ofullständigt Pressreleaser Ladda ner | Visa Stäng
2022-06-02 Immunovia Philipp Mathieu utnämnd till vd för Immunovia AB Pressreleaser Ladda ner | Visa Stäng
2022-06-02 Immunovia Philipp Mathieu appointed CEO of Immunovia AB Pressreleaser Ladda ner | Visa Stäng
2022-05-23 Immunovia Immunovia AB: Immunovia, Inc. market access increases when achieving Clinical Laboratory Permits from Pennsylvania and Maryland Departments of Health making IMMray™ PanCan-d test available in 48 US states Pressreleaser Ladda ner | Visa Stäng
2022-05-23 Immunovia Immunovia AB: Ökad marknadstillgång när Immunovia, Inc. erhåller licensrättigheter för kliniska laboratorier från Pennsylvanias och Marylands hälsodepartement Pressreleaser Ladda ner | Visa Stäng
2022-05-17 Immunovia Immunovia AB: Immunovia, Inc. erhåller licensrättigheter för kliniska laboratorier från Rhode Islands hälsodepartement vilket gör testet IMMray® PanCan-d tillgängligt i 46 amerikanska delstater Pressreleaser Ladda ner | Visa Stäng
2022-05-17 Immunovia Immunovia AB: Immunovia, Inc. achieves Clinical Laboratory Licensure from Rhode Island Dept of Health making IMMray™ PanCan-d test available in 46 US states Pressreleaser Ladda ner | Visa Stäng
2022-05-16 Immunovia Immunovia AB: Immunovia stärker sitt amerikanska team genom utnämningen av Natalie Carfora till Head of Market Access US Pressreleaser Ladda ner | Visa Stäng
2022-05-16 Immunovia Immunovia AB: Immunovia strengthens its US team through the appointment of Natalie Carfora as Head of Market Access US Pressreleaser Ladda ner | Visa Stäng
2022-04-28 Immunovia Immunovia AB: Immunovia Publishes Interim Report January-March 2022 Rapporter Ladda ner | Visa Stäng
2022-04-28 Immunovia Immunovia AB: Immunovia publicerar Delårsarapport januari-mars 2022 Rapporter Ladda ner | Visa Stäng
2022-04-21 Immunovia Immunovia AB: Inbjudan till Immunovias presentation av Q1 Pressreleaser Ladda ner | Visa Stäng
2022-04-21 Immunovia Immunovia AB: Invitation to Immunovia's Q1 presentation Pressreleaser Ladda ner | Visa Stäng
2022-04-14 Immunovia Immunovia AB: Immunovias ansökan om CPT® PLA-kod för testet IMMray™ PanCan-d på agendan hos American Medical Association Pressreleaser Ladda ner | Visa Stäng
2022-04-14 Immunovia Immunovia AB: Immunovia CPT PLA Code submission for the IMMray™ PanCan-d test is on the agenda of American Medical Association Pressreleaser Ladda ner | Visa Stäng
2022-04-07 Immunovia Kommuniké från årsstämma i Immunovia AB Pressreleaser Ladda ner | Visa Stäng
2022-04-07 Immunovia Communiqué from the Annual General Meeting in Immunovia AB Pressreleaser Ladda ner | Visa Stäng
2022-03-28 Immunovia Immunovia AB: Immunovia utser Jeff Borcherding, tidigare marknadschef på Myriad Genetics, till att leda Immunovias USA-verksamhet Pressreleaser Ladda ner | Visa Stäng
2022-03-28 Immunovia Immunovia AB: Immunovia appoints Jeff Borcherding, previously Chief Marketing Officer at Myriad Genetics, to lead Immunovia's US business Pressreleaser Ladda ner | Visa Stäng
2022-03-10 Immunovia Immunovia AB: Immunovia publicerar årsredovisningen för 2021 Pressreleaser Ladda ner | Visa Stäng
2022-03-10 Immunovia Immunovia AB: Immunovia publishes the annual report for 2021 Pressreleaser Ladda ner | Visa Stäng
2022-03-08 Immunovia Immunovia AB: Immunovia, Inc:s laboratorium erhåller ackreditering från College of American Pathologists - ett betydande steg i den rikstäckande utrullningen av IMMray® PanCan-d i USA Pressreleaser Ladda ner | Visa Stäng
2022-03-08 Immunovia Immunovia AB: Immunovia, Inc. Laboratory Receives Accreditation from College of American Pathologists - a major step in the nationwide US roll-out of IMMray™ PanCan-d Pressreleaser Ladda ner | Visa Stäng
2022-03-07 Immunovia Immunovia AB: Immunovia further strengthens IP portfolio for its IMMray™ PanCan-d signature Pressreleaser Ladda ner | Visa Stäng
2022-03-07 Immunovia Immunovia AB: Immunovia stärker IP-portföljen ytterligare för IMMray® PanCan-d-signaturen Pressreleaser Ladda ner | Visa Stäng
2022-03-04 Immunovia Notice to the Annual General Meeting of Immunovia AB (publ) Pressreleaser Ladda ner | Visa Stäng
2022-03-04 Immunovia Kallelse till årsstämma i Immunovia AB (publ) Pressreleaser Ladda ner | Visa Stäng
2022-02-22 Immunovia Immunovia AB: Immunovia invited to the 42nd Annual Cowen Health Care Conference Pressreleaser Ladda ner | Visa Stäng
2022-02-22 Immunovia Immunovia AB: Immunovia bjuds in till Cowens 42:a årliga hälso- och sjukvårdskonferens Pressreleaser Ladda ner | Visa Stäng
2022-02-17 Immunovia Immunovia AB: Immunovia publicerar Bokslutskommuniké 2021 Rapporter Ladda ner | Visa Stäng
2022-02-17 Immunovia Immunovia AB: Immunovia Publishes Full Year Report 2021 Rapporter Ladda ner | Visa Stäng
2022-02-17 Immunovia Immunovia AB: IMMray® PanCan-d - referensgranskad, blinda valideringsstudien publicerad i Clinical and Translational Gastroenterology Pressreleaser Ladda ner | Visa Stäng
2022-02-17 Immunovia Immunovia AB: IMMray™ PanCan-d - peer-reviewed, blinded validation study now published in Clinical and Translational Gastroenterology Pressreleaser Ladda ner | Visa Stäng
2022-02-04 Immunovia Immunovia AB: Inbjudan till Immunovias presentation av Q4 Pressreleaser Ladda ner | Visa Stäng
2022-02-04 Immunovia Immunovia AB: Invitation to Immunovia's Q4 presentation Pressreleaser Ladda ner | Visa Stäng
2022-02-03 Immunovia Immunovia AB: Immunovia postpones Annual General Meeting pending the Temporary Meetings Act Pressreleaser Ladda ner | Visa Stäng
2022-02-03 Immunovia Immunovia AB: Immunovia flyttar fram årsstämman beroende på den tillfälliga stämmolagen Pressreleaser Ladda ner | Visa Stäng
2022-01-20 Immunovia Immunovia AB: Immunovia appoints Philipp Mathieu as Acting CEO Pressreleaser Ladda ner | Visa Stäng
2022-01-20 Immunovia Immunovia AB: Immunovia utser Philipp Mathieu som tillförordnad vd Pressreleaser Ladda ner | Visa Stäng
2021-11-30 Immunovia Immunovia AB: Immunovia's CEO to step down during 2022 Pressreleaser Ladda ner | Visa Stäng
2021-11-26 Immunovia Immunovia AB: Immunovia appoints new Senior Director Investor Relations and Corporate Communications Pressreleaser Ladda ner | Visa Stäng
2021-11-26 Immunovia Immunovia AB: Immunovia utser ny Senior Director Investor Relations and Corporate Communications Pressreleaser Ladda ner | Visa Stäng
2021-11-23 Immunovia Immunovia AB: Immunovia högtidliggjorde World Pancreatic Cancer Day genom att fira invigningen av det amerikanska dotterbolaget Immunovia, Inc. Pressreleaser Ladda ner | Visa Stäng
2021-11-23 Immunovia Immunovia AB: Immunovia Honored World Pancreatic Cancer Day by a Grand Opening Celebration of the US Subsidiary Immunovia, Inc. Pressreleaser Ladda ner | Visa Stäng
2021-11-11 Immunovia Immunovia AB: Immunovia Publishes Report for the Third Quarter 2021 Rapporter Ladda ner | Visa Stäng
2021-11-11 Immunovia Immunovia AB: Immunovia publicerar rapport för tredje kvartalet 2021 Rapporter Ladda ner | Visa Stäng
2021-11-05 Immunovia Immunovia AB: Immunovia to Present at Jefferies London Healthcare Conference Pressreleaser Ladda ner | Visa Stäng
2021-11-05 Immunovia Immunovia AB: Immunovia presenterar på Jefferies London Healthcare Conference Pressreleaser Ladda ner | Visa Stäng
2021-10-29 Immunovia Immunovia AB: Immunovia, Inc.'s Medical Director Dr. Thomas King inbjuden som huvudtalare av US National Cancer Institute Pressreleaser Ladda ner | Visa Stäng
2021-10-29 Immunovia Immunovia AB: Immunovia, Inc.'s Medical Director Dr. Thomas King Invited as Keynote Speaker by US National Cancer Institute Pressreleaser Ladda ner | Visa Stäng
2021-10-29 Immunovia Immunovia AB: Inbjudan till presentation av Immunovias delårsrapport januari - september 2021 Pressreleaser Ladda ner | Visa Stäng
2021-10-29 Immunovia Immunovia AB: Invitation to Presentation of Immunovia's Interim Report January - September 2021 Pressreleaser Ladda ner | Visa Stäng
2021-10-28 Immunovia Immunovia AB: Immunovia tilldelas utmärkelsen Presidential Poster Award vid American College of Gastroenterology's årliga vetenskapskonferens Pressreleaser Ladda ner | Visa Stäng
2021-10-28 Immunovia Immunovia AB: Immunovia receives Presidential Poster Award at the American College of Gastroenterology Annual Scientific Meeting Pressreleaser Ladda ner | Visa Stäng
2021-10-25 Immunovia Valberedning utsedd inför årsstämma 2022 i Immunovia AB (Publ) Pressreleaser Ladda ner | Visa Stäng
2021-10-25 Immunovia Nomination Committee appointed for the 2022 Annual General Meeting of Immunovia AB (Publ) Pressreleaser Ladda ner | Visa Stäng
2021-10-15 Immunovia Immunovia AB: Immunovia utser ny Chief Financial Officer Pressreleaser Ladda ner | Visa Stäng
2021-10-15 Immunovia Immunovia AB: Immunovia Appoints New Chief Financial Officer Pressreleaser Ladda ner | Visa Stäng
2021-09-24 Immunovia Immunovia AB: Vator Securities: Unleashing a paradigm shift in early detection of pancreatic cancer Pressreleaser Ladda ner | Visa Stäng
2021-09-14 Immunovia Immunovia AB: USA-baserade Pancreatic Cancer Action Network informerar sina medlemmar om Immunovias blodtest IMMray® PanCan-d Pressreleaser Ladda ner | Visa Stäng
2021-09-14 Immunovia Immunovia AB: The US based Pancreatic Cancer Action Network informs their members about Immunovia's blood test IMMray™ PanCan-d Pressreleaser Ladda ner | Visa Stäng
2021-09-13 Immunovia Immunovia AB: Immunovia enters licensing agreement with JW BioScience for pancreatic cancer biomarkers Pressreleaser Ladda ner | Visa Stäng
2021-09-13 Immunovia Immunovia AB: Immunovia ingår licensavtal med JW BioScience avseende biomarkörer för bukspottkörtelcancer Pressreleaser Ladda ner | Visa Stäng
2021-09-03 Immunovia Immunovia AB: Styrelseledamot i Immunovia köper aktier i bolaget Pressreleaser Ladda ner | Visa Stäng
2021-09-03 Immunovia Immunovia AB: Board member of Immunovia purchases shares in the company Pressreleaser Ladda ner | Visa Stäng
2021-08-19 Immunovia Immunovia AB: Immunovia Publishes Report for the Second Quarter 2021 Rapporter Ladda ner | Visa Stäng
2021-08-19 Immunovia Immunovia AB: Immunovia publicerar rapport för andra kvartalet 2021 Rapporter Ladda ner | Visa Stäng
2021-08-11 Immunovia Immunovia AB: Invitation to Presentation of Immunovia's Interim Report January - June 2021 Pressreleaser Ladda ner | Visa Stäng
2021-08-11 Immunovia Immunovia AB: Inbjudan till presentation av Immunovias delårsrapport januari - juni 2021 Pressreleaser Ladda ner | Visa Stäng
2021-08-10 Immunovia Immunovia AB: Immunovia presenterar listpris för IMMray® PanCan-d i USA och förbättrad prestanda i den familjära/ärftliga riskgruppen Pressreleaser Ladda ner | Visa Stäng
2021-08-10 Immunovia Immunovia AB: Immunovia Provides Updates on the Price for the IMMray[TM] PanCan-d Test in the US and Improved Test Performance in the Familial/Hereditary Risk Group Pressreleaser Ladda ner | Visa Stäng
2021-08-04 Immunovia Immunovia AB: Immunovia Inc. får godkänt att använda testet IMMray® PanCan-d för tidig upptäckt av bukspottkörtelcancer i USA Pressreleaser Ladda ner | Visa Stäng
2021-08-04 Immunovia Immunovia AB: Immunovia, Inc. Receives Approval to Begin Testing Patients for Pancreatic Cancer with the IMMray™ PanCan-d Test Pressreleaser Ladda ner | Visa Stäng
2021-06-30 Immunovia Immunovia AB: Immunovia, Inc. erhåller lagstadgat registreringsbevis - licensieringen av laboratoriet pågår fortfarande Pressreleaser Ladda ner | Visa Stäng
2021-06-30 Immunovia Immunovia AB: Immunovia, Inc. Receives Certificate of Registration - Clinical Laboratory Licensure Still Pending Pressreleaser Ladda ner | Visa Stäng
2021-05-28 Immunovia Immunovia AB: Verkställande direktör Patrik Dahlen köper aktier i Immunovia Pressreleaser Ladda ner | Visa Stäng
2021-05-28 Immunovia Immunovia AB: CEO Patrik Dahlen purchases Immunovia shares Pressreleaser Ladda ner | Visa Stäng
2021-05-27 Immunovia Immunovia AB: Immunovia to Host a Key Opinion Leader Event on the Clinical Use of IMMray™ PanCan-d Pressreleaser Ladda ner | Visa Stäng
2021-05-27 Immunovia Immunovia AB: Immunovia bjuder in till key opinion leader event om den kliniska användningen av IMMray® PanCan-d Pressreleaser Ladda ner | Visa Stäng
2021-05-20 Finansinspektionen Finansinspektionen: Flaggningsmeddelande i Immunovia AB (publ) Pressreleaser Visa Stäng
2021-05-12 Immunovia Immunovia AB: Styrelseledamot i Immunovia köper aktier i bolaget Pressreleaser Ladda ner | Visa Stäng
2021-05-12 Immunovia Immunovia AB: Member of Immunovia's Board of Directors purchases shares in the company Pressreleaser Ladda ner | Visa Stäng
2021-05-06 Immunovia Annual General Meeting - Immunovia AB Pressreleaser Ladda ner | Visa Stäng
2021-05-06 Immunovia Kommuniké från årsstämma i Immunovia AB Pressreleaser Ladda ner | Visa Stäng
2021-05-04 Immunovia Immunovia AB: Members of Immunovia's Board of Directors purchase shares in the company Pressreleaser Ladda ner | Visa Stäng
2021-05-04 Immunovia Immunovia AB: Styrelseledamöter i Immunovia köper aktier i bolaget Pressreleaser Ladda ner | Visa Stäng
2021-04-29 Finansinspektionen Finansinspektionen: Flaggningsmeddelande i Immunovia AB (publ) Pressreleaser Visa Stäng
2021-04-28 Immunovia Immunovia AB: Immunovia publicerar delårsrapport januari - mars 2021 Rapporter Ladda ner | Visa Stäng
2021-04-28 Immunovia Immunovia AB: Immunovia Reports Interim Report January - March 2021 Rapporter Ladda ner | Visa Stäng
2021-04-22 Immunovia Immunovia AB: Immunovias process för att uppnå kostnadsersättning för IMMray[®] PanCan-d Pressreleaser Ladda ner | Visa Stäng
2021-04-22 Immunovia Immunovia AB: Immunovia reiterates its road to reimbursement for the IMMray™ PanCan-d test Pressreleaser Ladda ner | Visa Stäng
2021-04-21 Immunovia Immunovia AB: Immunovia presenterar uppdatering av marknadens storlek i USA för IMMray® PanCan-d i den familjära/ärftliga riskgruppen Pressreleaser Ladda ner | Visa Stäng
2021-04-21 Immunovia Immunovia AB: Immunovia presents update on US market size for IMMray™ PanCan-d in the familial/hereditary risk group Pressreleaser Ladda ner | Visa Stäng
2021-04-21 Immunovia Immunovia AB: Inbjudan till presentation av Immunovias delårsrapport januari - mars 2021 Pressreleaser Ladda ner | Visa Stäng
2021-04-21 Immunovia Immunovia AB: Invitation to Presentation of Immunovia's Interim Report January - March 2021 Pressreleaser Ladda ner | Visa Stäng
2021-04-16 Immunovia Immunovia AB: IMMray™ PanCan-d highlighted in meeting arranged by Pancreatic Cancer Action Network Pressreleaser Ladda ner | Visa Stäng
2021-04-16 Immunovia Immunovia AB: IMMray[®] PanCan-d uppmärksammades i möte arrangerat av Pancreatic Cancer Action Network Pressreleaser Ladda ner | Visa Stäng
2021-03-31 Immunovia Immunovia AB: KALLELSE TILL ÅRSSTÄMMA I IMMUNOVIA AB Pressreleaser Ladda ner | Visa Stäng
2021-03-29 Immunovia Immunovia AB: Immunovia rapporterar förbättrad testprestanda för IMMray ® PanCan-d för upptäckt av bukspottkörtelcancer i tidigt stadium hos högriskpatienter med symptom Pressreleaser Ladda ner | Visa Stäng
2021-03-29 Immunovia Immunovia AB: Immunovia reports positive results of the blinded clinical validation of IMMray[TM] PanCan-d blood test in USA Pressreleaser Ladda ner | Visa Stäng
2021-03-29 Immunovia Immunovia AB: Immunovia reports improved test performance of IMMray[TM] PanCan-d in detecting early stage pancreatic cancer in high risk symptomatic patients Pressreleaser Ladda ner | Visa Stäng
2021-03-29 Immunovia Immunovia AB: Immunovia rapporterar positiva resultat för IMMray ® PanCan-d blodbaserade test i blindad klinisk valideringsstudie utförd i USA Pressreleaser Ladda ner | Visa Stäng
2021-03-29 Immunovia Immunovia AB: Vator Securities: Thou shall reimburse the one who finds the silent killer Pressreleaser Ladda ner | Visa Stäng
2021-03-12 Immunovia Immunovia AB: Immunovia publicerar årsredovisningen för räkenskapsåret 2020 Rapporter Ladda ner | Visa Stäng
2021-03-12 Immunovia Immunovia AB: Immunovia publishes the annual report for the financial year 2020 Rapporter Ladda ner | Visa Stäng
2021-02-26 Immunovia Immunovia AB: Immunovia publishes data sets on the Optimization Study and Commercial Test Model Study Pressreleaser Ladda ner | Visa Stäng
2021-02-26 Immunovia Immunovia AB: Immunovia publicerar datan från Optimeringsstudien och Commercial Test Model Study Pressreleaser Ladda ner | Visa Stäng
2021-02-17 Immunovia Immunovia AB: Immunovia Full Year Report 2020 Rapporter Ladda ner | Visa Stäng
2021-02-17 Immunovia Immunovia AB: Immunovia Bokslutskommuniké 2020 Rapporter Ladda ner | Visa Stäng
2021-02-15 Immunovia Immunovia AB: Immunovias PanFAM-1 prospektiva studie samlar över 3000 prover från patienter med risk för familjär/ärftlig bukspottkörtelcancer för analys under andra halvåret 2021 Pressreleaser Ladda ner | Visa Stäng
2021-02-15 Immunovia Immunovia AB: Immunovia's PanFAM-1 Prospective Study Gathers Over 3000 Familial Hereditary Pancreatic Cancer Risk Samples And Will Be Analysed In The Second Half Of 2021 Pressreleaser Ladda ner | Visa Stäng
2021-02-15 Finansinspektionen Finansinspektionen: Flaggningsmeddelande i Immunovia AB (publ) Pressreleaser Visa Stäng
2021-02-11 Immunovia Immunovia AB: Inbjudan till presentation av Immunovia's bokslutskommuniké 2020 den 17 februari 2021 Pressreleaser Ladda ner | Visa Stäng
2021-02-11 Immunovia Immunovia AB: Invitation to presentation of Immunovia's Full Year Report 2020 on February 17, 2021 Pressreleaser Ladda ner | Visa Stäng
2021-02-10 Immunovia Immunovia AB: Immunovia på väg mot försäljningsstart av IMMray ® PanCan-d under första kvartalet, 2021 Pressreleaser Ladda ner | Visa Stäng
2021-02-10 Immunovia Immunovia AB: Immunovia On Track For IMMray™ PanCan-d Sales Start In Q1 2021 Pressreleaser Ladda ner | Visa Stäng
2021-01-19 Immunovia Immunovia AB: Verkställande direktör Patrik Dahlen köper Immunovia teckningsoptioner Pressreleaser Ladda ner | Visa Stäng
2021-01-19 Immunovia Immunovia AB: Chief Executive Officer, Patrik Dahlen Buys Immunovia Warrants Pressreleaser Ladda ner | Visa Stäng
2021-01-07 Immunovia Immunovia AB: Proteomdata baserade på Immunovias IMMray® -plattform möjliggör differentialdiagnos av svårbedömda autoimmuna sjukdomar Pressreleaser Ladda ner | Visa Stäng
2021-01-07 Immunovia Immunovia AB: Proteomic data derived from Immunovia's IMMray™-platform allows differential diagnosis of difficult to distinguish autoimmune diseases Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

24 Aug 2022 | Kvartalsrapport 2022-Q2
10 Nov 2022 | Kvartalsrapport 2022-Q3
9 Feb 2023 | Bokslutskommuniké 2022